• Home
  • EPCO-12. IN VIVO PERTURB-SEQ DEFINES BIOLOGICAL DRIVERS AND THERAPEUTIC VULNERABILITIES UNDERLYING RADIOTHERAPY RESISTANCE IN GLIOBLASTOMA.

EPCO-12. IN VIVO PERTURB-SEQ DEFINES BIOLOGICAL DRIVERS AND THERAPEUTIC VULNERABILITIES UNDERLYING RADIOTHERAPY RESISTANCE IN GLIOBLASTOMA.

Author List
John Liu, Joanna Pak, Christopher Zou, Sixuan Pan, Emily Payne, Kyla Foster, Katie Lin, Tim Casey-Clyde, Kyounghee Seo, Thomas O'Loughlin, David Wu, Daniel Lim, Harish Vasudevan, Aaron Diaz, Tomoko Ozawa, Mitchel Berger, John de Groot, William Weiss, Luke Gilbert, David Raleigh
Publication
Neuro-oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/453495574
Publication Year
2023
Publication Title
John Liu, Joanna Pak, Christopher Zou, Sixuan Pan, Emily Payne, Kyla Foster, Katie Lin, Tim Casey-Clyde, Kyounghee Seo, Thomas O'Loughlin, David Wu, Daniel Lim, Harish Vasudevan, Aaron Diaz, Tomoko Ozawa, Mitchel Berger, John de Groot, William Weiss, Luke Gilbert, David Raleigh. EPCO-12. IN VIVO PERTURB-SEQ DEFINES BIOLOGICAL DRIVERS AND THERAPEUTIC VULNERABILITIES UNDERLYING RADIOTHERAPY RESISTANCE IN GLIOBLASTOMA. Neuro-Oncology. 2023 Nov 10; 25(Supplement_5):v125-v126.